Status:
WITHDRAWN
Natural History of Levodopa-Induced Dyskinesia (LID)
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Oregon Clinical and Translational Research Institute
Conditions:
Parkinson's Disease
Eligibility:
All Genders
21-100 years
Brief Summary
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias (LID). The severity of these movements can range from subtle to e...
Detailed Description
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of these movements can ...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson's disease
- At least 21 years of age
- Levodopa treatment that will be orally initiated no more than 1 month after the screening visit for the study.
Exclusion
- Unable to stand for 1 minute intervals
- Sensory deficits in the feet
- Significant cognitive impairment
- Unstable medical or psychiatric conditions (including hallucinations)
- History of dopamine receptor blocking medications (Haldol, Orap, Zyprexa)
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01003002
Start Date
December 1 2010
End Date
December 1 2020
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239